English

SORRENTO THERAPEUTICS, INC.

EDGAR

SRNE Quarterly report (10-Q) · filed 2023-08-14

126 filing records in this dataset, filed from 2006-07-14 to 2023-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

13 million USD

2019 Q4 · USD

Exact inputs and evidence

Revenue: 13034000 USD Source

Operating margin

-249.95%

2019 Q4 · %

Exact inputs and evidence

Operating Income: -259393000 USD Source
Operating Income: -226814000 USD Source
Revenue: 13034000 USD Source

Operating cash flow

-36 million USD

2019 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -172996000 USD Source
Operating Cash Flow: -136974000 USD Source

Free cash flow

-37.9 million USD

2019 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -172996000 USD Source
Operating Cash Flow: -136974000 USD Source
Capital Expenditure: 11442000 USD Source
Capital Expenditure: 9582000 USD Source

Cash and cash equivalents: 69.7 million USD 2023-06-30 Source
Exact value

69749000 USD
Long-term debt including current maturities: 5.21 million USD 2017-12-31 Source
Exact value

5211000 USD
Shares outstanding: 551 million shares 2023-06-30 Source
Exact value

551281154 shares

Reported share-count change

26.32% · 115 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

436418964 shares · 2022-06-30· Source
551281154 shares · 2023-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

31.4 million USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Revenue: 6143000 USD · 2019-01-01 – 2019-03-31 Source
Revenue: 6477000 USD · 2019-04-01 – 2019-06-30 Source
Revenue: 5778000 USD · 2019-07-01 – 2019-09-30 Source
Revenue: 13034000 USD · 2019-10-01 – 2019-12-31 Source

Net income

-548 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Net income: -89576000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -572843000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -349151000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -139616000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -95212000 USD · 2023-04-01 – 2023-06-30 Source

Operating cash flow

-235 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -225519000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -164348000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -293857000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -225519000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -49459000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -105118000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -49459000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

8.59 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Capital expenditure: 9133000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 5298000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 13657000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 9133000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 86000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 226000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 86000 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-243 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -225519000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -164348000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -293857000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -225519000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -49459000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -105118000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -49459000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 9133000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 5298000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 13657000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 9133000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 86000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 226000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 86000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-08-14.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2019-12-31
Operating income: 11 of 11 periods available· newest 2022-12-31
Net income: 11 of 11 periods available· newest 2022-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
Capital expenditure: 11 of 11 periods available· newest 2022-12-31
Total assets: 11 of 11 periods available· newest 2022-12-31
Total liabilities: 9 of 11 periods available· newest 2022-12-31
Current assets: 11 of 11 periods available· newest 2022-12-31
Current liabilities: 11 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2017-12-31
Shares outstanding: 11 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 144.52 million

Prior period

−USD 428.33 million

2021-01-01 – 2021-12-31
Current period

−USD 572.84 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-572843000 − -428325000 = -144518000 USD

-428325000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-572843000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Year-over-year change in Net income: -144518000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -572843000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#6374079 Filing: 000095017023008238 Input fundies:NetIncome: -428325000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#6376335 Filing: 000095017023008238
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 12.04 million

Prior period

−USD 281.82 million

2021-01-01 – 2021-12-31
Current period

−USD 293.86 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-293857000 − -281821000 = -12036000 USD

-281821000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-293857000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Year-over-year change in Operating cash flow: -12036000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -293857000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4285563 Filing: 000095017023008238 Input fundies:OperatingCashFlow: -281821000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4287758 Filing: 000095017023008238
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+54%

Prior period

USD 8.87 million

2021-01-01 – 2021-12-31
Current period

USD 13.66 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

13657000 − 8871000 = 4786000 USD

8871000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
13657000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Year-over-year change in Capital expenditure: 4786000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 13657000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4302587 Filing: 000095017023008238 Input fundies:CapitalExpenditure: 8871000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4304772 Filing: 000095017023008238
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 31.43 million 100% of revenue
Operating costs Derived USD 290.83 million 925% of revenue
Operating income −USD 259.39 million −825% of revenue
Tax, interest and other Derived USD 32.68 million 104% of revenue
Net income −USD 292.07 million −929% of revenue

Cash

Operating cash flow −USD 173 million −550% of revenue
Capital expenditure USD 11.44 million 36% of revenue
Free cash flow Derived −USD 184.44 million −587% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 4,810% of revenue.
2014 Operating loss: operating costs were 1,008% of revenue.
2015 Operating loss: operating costs were 1,712% of revenue.
2016 Operating loss: operating costs were 1,287% of revenue.
2017 11%83%
2018 Operating loss: operating costs were 810% of revenue.
2019 Operating loss: operating costs were 925% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	460000	22128000 Derived	-21668000	243000 Derived	-21911000	-16909000 Derived	Source 2013-01-01 – 2013-12-31: 460000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -21668000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -21911000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -16489000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 420000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	3825000	38567000 Derived	-34742000	-85000 Derived	-34657000	-29355000 Derived	Source 2014-01-01 – 2014-12-31: 3825000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -34742000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -34657000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -28764000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 591000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	4590000	78595000 Derived	-74005000	-28194000 Derived	-45811000	-45776000 Derived	Source 2015-01-01 – 2015-12-31: 4590000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -74005000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -45811000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -42069000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 3707000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	8152000	104929000 Derived	-96777000	-35854000 Derived	-60923000	-77788000 Derived	Source 2016-01-01 – 2016-12-31: 8152000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -96777000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -60923000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -70928000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 6860000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	151856000	126521000 Derived	25335000	16203000 Derived	9132000	-110152000 Derived	Source 2017-01-01 – 2017-12-31: 151856000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 25335000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 9132000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -99180000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 10972000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	21193000	171618000 Derived	-150425000	53115000 Derived	-203540000	-122962000 Derived	Source 2018-01-01 – 2018-12-31: 21193000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -150425000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -203540000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -111767000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 11195000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	31432000	290825000 Derived	-259393000	32675000 Derived	-292068000	-184438000 Derived	Source 2019-01-01 – 2019-12-31: 31432000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -259393000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -292068000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -172996000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 11442000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 31.4M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	584000	Revenue: 584000 Open source
20132013-12-31	Revenue	460000	Revenue: 460000 Open source
20142014-12-31	Revenue	3825000	Revenue: 3825000 Open source
20152015-12-31	Revenue	4590000	Revenue: 4590000 Open source
20162016-12-31	Revenue	8152000	Revenue: 8152000 Open source
20172017-12-31	Revenue	151856000	Revenue: 151856000 Open source
20182018-12-31	Revenue	21193000	Revenue: 21193000 Open source
20192019-12-31	Revenue	31432000	Revenue: 31432000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

48.3% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 584000 Open source
20132013-12-31	Year over year	-21.2%	Revenue: 460000 Open source Revenue: 584000 Open source
20142014-12-31	Year over year	731.5%	Revenue: 3825000 Open source Revenue: 460000 Open source
20152015-12-31	Year over year	20%	Revenue: 4590000 Open source Revenue: 3825000 Open source
20162016-12-31	Year over year	77.6%	Revenue: 8152000 Open source Revenue: 4590000 Open source
20172017-12-31	Year over year	1,762.8%	Revenue: 151856000 Open source Revenue: 8152000 Open source
20182018-12-31	Year over year	-86%	Revenue: 21193000 Open source Revenue: 151856000 Open source
20192019-12-31	Year over year	48.3%	Revenue: 31432000 Open source Revenue: 21193000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -825.3% 2019

Net margin -929.2% 2019

Free cash flow margin -586.8% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-830.8%	Operating Income: -4852000 Open source Revenue: 584000 Open source
20132013-12-31	Operating margin	-4,710.4%	Operating Income: -21668000 Open source Revenue: 460000 Open source
20142014-12-31	Operating margin	-908.3%	Operating Income: -34742000 Open source Revenue: 3825000 Open source
20152015-12-31	Operating margin	-1,612.3%	Operating Income: -74005000 Open source Revenue: 4590000 Open source
20162016-12-31	Operating margin	-1,187.2%	Operating Income: -96777000 Open source Revenue: 8152000 Open source
20172017-12-31	Operating margin	16.7%	Operating Income: 25335000 Open source Revenue: 151856000 Open source
20182018-12-31	Operating margin	-709.8%	Operating Income: -150425000 Open source Revenue: 21193000 Open source
20192019-12-31	Operating margin	-825.3%	Operating Income: -259393000 Open source Revenue: 31432000 Open source
20122012-12-31	Net margin	-829.6%	Net Income: -4845000 Open source Revenue: 584000 Open source
20132013-12-31	Net margin	-4,763.3%	Net Income: -21911000 Open source Revenue: 460000 Open source
20142014-12-31	Net margin	-906.1%	Net Income: -34657000 Open source Revenue: 3825000 Open source
20152015-12-31	Net margin	-998.1%	Net Income: -45811000 Open source Revenue: 4590000 Open source
20162016-12-31	Net margin	-747.3%	Net Income: -60923000 Open source Revenue: 8152000 Open source
20172017-12-31	Net margin	6%	Net Income: 9132000 Open source Revenue: 151856000 Open source
20182018-12-31	Net margin	-960.4%	Net Income: -203540000 Open source Revenue: 21193000 Open source
20192019-12-31	Net margin	-929.2%	Net Income: -292068000 Open source Revenue: 31432000 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 584000 Open source
20132013-12-31	Free cash flow margin	-3,675.9%	Revenue: 460000 Open source Operating Cash Flow: -16489000 Open source Capital Expenditure: 420000 Open source
20142014-12-31	Free cash flow margin	-767.5%	Revenue: 3825000 Open source Operating Cash Flow: -28764000 Open source Capital Expenditure: 591000 Open source
20152015-12-31	Free cash flow margin	-997.3%	Revenue: 4590000 Open source Operating Cash Flow: -42069000 Open source Capital Expenditure: 3707000 Open source
20162016-12-31	Free cash flow margin	-954.2%	Revenue: 8152000 Open source Operating Cash Flow: -70928000 Open source Capital Expenditure: 6860000 Open source
20172017-12-31	Free cash flow margin	-72.5%	Revenue: 151856000 Open source Operating Cash Flow: -99180000 Open source Capital Expenditure: 10972000 Open source
20182018-12-31	Free cash flow margin	-580.2%	Revenue: 21193000 Open source Operating Cash Flow: -111767000 Open source Capital Expenditure: 11195000 Open source
20192019-12-31	Free cash flow margin	-586.8%	Revenue: 31432000 Open source Operating Cash Flow: -172996000 Open source Capital Expenditure: 11442000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -173M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	Not reported	No source recorded
20132013-12-31	Operating cash flow	-16489000	Operating Cash Flow: -16489000 Open source
20142014-12-31	Operating cash flow	-28764000	Operating Cash Flow: -28764000 Open source
20152015-12-31	Operating cash flow	-42069000	Operating Cash Flow: -42069000 Open source
20162016-12-31	Operating cash flow	-70928000	Operating Cash Flow: -70928000 Open source
20172017-12-31	Operating cash flow	-99180000	Operating Cash Flow: -99180000 Open source
20182018-12-31	Operating cash flow	-111767000	Operating Cash Flow: -111767000 Open source
20192019-12-31	Operating cash flow	-172996000	Operating Cash Flow: -172996000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -184.4M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	Unavailable	No source recorded
20132013-12-31	Free cash flow	-16909000	Operating Cash Flow: -16489000 Open source Capital Expenditure: 420000 Open source
20142014-12-31	Free cash flow	-29355000	Operating Cash Flow: -28764000 Open source Capital Expenditure: 591000 Open source
20152015-12-31	Free cash flow	-45776000	Operating Cash Flow: -42069000 Open source Capital Expenditure: 3707000 Open source
20162016-12-31	Free cash flow	-77788000	Operating Cash Flow: -70928000 Open source Capital Expenditure: 6860000 Open source
20172017-12-31	Free cash flow	-110152000	Operating Cash Flow: -99180000 Open source Capital Expenditure: 10972000 Open source
20182018-12-31	Free cash flow	-122962000	Operating Cash Flow: -111767000 Open source Capital Expenditure: 11195000 Open source
20192019-12-31	Free cash flow	-184438000	Operating Cash Flow: -172996000 Open source Capital Expenditure: 11442000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

94.1% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Liabilities / assets	Not reported	Total Assets: 6781604 Open source
2013-12-31	Liabilities / assets	Not reported	Total Assets: 92582000 Open source
20142014-12-31	Liabilities / assets	23.2%	Total Liabilities: 32828000 Open source Total Assets: 141541000 Open source
20152015-12-31	Liabilities / assets	59%	Total Liabilities: 202581000 Open source Total Assets: 343519000 Open source
20162016-12-31	Liabilities / assets	78.5%	Total Liabilities: 315084000 Open source Total Assets: 401586000 Open source
20172017-12-31	Liabilities / assets	52.1%	Total Liabilities: 225003000 Open source Total Assets: 431613000 Open source
20182018-12-31	Liabilities / assets	66.8%	Total Liabilities: 416587000 Open source Total Assets: 624087000 Open source
20192019-12-31	Liabilities / assets	94.1%	Total Liabilities: 524876000 Open source Total Assets: 557632000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.59× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Current assets / current liabilities	8.99×	Current Assets: 5251990 Open source Current Liabilities: 584173 Open source
20132013-12-31	Current assets / current liabilities	5.95×	Current Assets: 32632000 Open source Current Liabilities: 5480000 Open source
20142014-12-31	Current assets / current liabilities	7.73×	Current Assets: 73915000 Open source Current Liabilities: 9557000 Open source
20152015-12-31	Current assets / current liabilities	4.57×	Current Assets: 141018000 Open source Current Liabilities: 30873000 Open source
20162016-12-31	Current assets / current liabilities	1.18×	Current Assets: 89654000 Open source Current Liabilities: 76085000 Open source
20172017-12-31	Current assets / current liabilities	0.38×	Current Assets: 29700000 Open source Current Liabilities: 78955000 Open source
20182018-12-31	Current assets / current liabilities	2.91×	Current Assets: 179564000 Open source Current Liabilities: 61621000 Open source
20192019-12-31	Current assets / current liabilities	0.59×	Current Assets: 67588000 Open source Current Liabilities: 115206000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 21.91 million Exact value Exact value: -21911000 USD 2013-01-01 – 2013-12-31: -21911000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2013-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -21911000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21911000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459016014768/srne-20151231.xml#250136 Filing: 000156459016014768 The citation records this snapshot. The page link may show a newer release later.	−USD 16.49 million Exact value Exact value: -16489000 USD 2013-01-01 – 2013-12-31: -16489000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2013-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -16489000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16489000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459016014768/srne-20151231.xml#326683 Filing: 000156459016014768 The citation records this snapshot. The page link may show a newer release later.	USD 420,000 Exact value Exact value: 420000 USD 2013-01-01 – 2013-12-31: 420000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2013-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 420000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 420000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459016014768/srne-20151231.xml#327354 Filing: 000156459016014768 The citation records this snapshot. The page link may show a newer release later.	−USD 16.91 million Calculation and evidence -16489000 − 420000 USD Exact free cash flow: -16909000 USD 2013-01-01 – 2013-12-31: -16489000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 420000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2013-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -16909000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16489000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459016014768/srne-20151231.xml#326683 Filing: 000156459016014768 Input fundies:CapitalExpenditure: 420000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459016014768/srne-20151231.xml#327354 Filing: 000156459016014768 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 34.66 million Exact value Exact value: -34657000 USD 2014-01-01 – 2014-12-31: -34657000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2014-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -34657000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34657000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459017005329/srne-20161231.xml#313481 Filing: 000156459017005329 The citation records this snapshot. The page link may show a newer release later.	−USD 28.76 million Exact value Exact value: -28764000 USD 2014-01-01 – 2014-12-31: -28764000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2014-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -28764000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28764000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459017005329/srne-20161231.xml#356088 Filing: 000156459017005329 The citation records this snapshot. The page link may show a newer release later.	USD 591,000 Exact value Exact value: 591000 USD 2014-01-01 – 2014-12-31: 591000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2014-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 591000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 591000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459017005329/srne-20161231.xml#356760 Filing: 000156459017005329 The citation records this snapshot. The page link may show a newer release later.	−USD 29.36 million Calculation and evidence -28764000 − 591000 USD Exact free cash flow: -29355000 USD 2014-01-01 – 2014-12-31: -28764000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 591000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2014-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -29355000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28764000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459017005329/srne-20161231.xml#356088 Filing: 000156459017005329 Input fundies:CapitalExpenditure: 591000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459017005329/srne-20161231.xml#356760 Filing: 000156459017005329 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 45.81 million Exact value Exact value: -45811000 USD 2015-01-01 – 2015-12-31: -45811000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2015-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -45811000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45811000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026118000013/srne-20171231.xml#559959 Filing: 000085026118000013 The citation records this snapshot. The page link may show a newer release later.	−USD 42.07 million Exact value Exact value: -42069000 USD 2015-01-01 – 2015-12-31: -42069000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2015-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -42069000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42069000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026118000013/srne-20171231.xml#559323 Filing: 000085026118000013 The citation records this snapshot. The page link may show a newer release later.	USD 3.71 million Exact value Exact value: 3707000 USD 2015-01-01 – 2015-12-31: 3707000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2015-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 3707000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3707000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026118000013/srne-20171231.xml#588858 Filing: 000085026118000013 The citation records this snapshot. The page link may show a newer release later.	−USD 45.78 million Calculation and evidence -42069000 − 3707000 USD Exact free cash flow: -45776000 USD 2015-01-01 – 2015-12-31: -42069000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 3707000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2015-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -45776000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42069000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026118000013/srne-20171231.xml#559323 Filing: 000085026118000013 Input fundies:CapitalExpenditure: 3707000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026118000013/srne-20171231.xml#588858 Filing: 000085026118000013 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 60.92 million Exact value Exact value: -60923000 USD 2016-01-01 – 2016-12-31: -60923000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2016-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -60923000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60923000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/srne-20181231.xml#671215 Filing: 000085026119000002 The citation records this snapshot. The page link may show a newer release later.	−USD 70.93 million Exact value Exact value: -70928000 USD 2016-01-01 – 2016-12-31: -70928000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2016-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -70928000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70928000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/srne-20181231.xml#670578 Filing: 000085026119000002 The citation records this snapshot. The page link may show a newer release later.	USD 6.86 million Exact value Exact value: 6860000 USD 2016-01-01 – 2016-12-31: 6860000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2016-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 6860000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6860000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/srne-20181231.xml#698082 Filing: 000085026119000002 The citation records this snapshot. The page link may show a newer release later.	−USD 77.79 million Calculation and evidence -70928000 − 6860000 USD Exact free cash flow: -77788000 USD 2016-01-01 – 2016-12-31: -70928000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6860000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2016-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -77788000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70928000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/srne-20181231.xml#670578 Filing: 000085026119000002 Input fundies:CapitalExpenditure: 6860000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026119000002/srne-20181231.xml#698082 Filing: 000085026119000002 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 9.13 million Exact value Exact value: 9132000 USD 2017-01-01 – 2017-12-31: 9132000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2017-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: 9132000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 9132000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/srne-20191231.htm#4120593 Filing: 000085026120000027 The citation records this snapshot. The page link may show a newer release later.	−USD 99.18 million Exact value Exact value: -99180000 USD 2017-01-01 – 2017-12-31: -99180000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2017-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -99180000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -99180000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/srne-20191231.htm#2652507 Filing: 000085026120000027 The citation records this snapshot. The page link may show a newer release later.	USD 10.97 million Exact value Exact value: 10972000 USD 2017-01-01 – 2017-12-31: 10972000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2017-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 10972000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10972000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/srne-20191231.htm#2659092 Filing: 000085026120000027 The citation records this snapshot. The page link may show a newer release later.	−USD 110.15 million Calculation and evidence -99180000 − 10972000 USD Exact free cash flow: -110152000 USD 2017-01-01 – 2017-12-31: -99180000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 10972000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2017-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -110152000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -99180000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/srne-20191231.htm#2652507 Filing: 000085026120000027 Input fundies:CapitalExpenditure: 10972000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000085026120000027/srne-20191231.htm#2659092 Filing: 000085026120000027 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 203.54 million Exact value Exact value: -203540000 USD 2018-01-01 – 2018-12-31: -203540000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2018-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -203540000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -203540000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm#5211196 Filing: 000156459021006983 The citation records this snapshot. The page link may show a newer release later.	−USD 111.77 million Exact value Exact value: -111767000 USD 2018-01-01 – 2018-12-31: -111767000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2018-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -111767000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -111767000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm#3511793 Filing: 000156459021006983 The citation records this snapshot. The page link may show a newer release later.	USD 11.2 million Exact value Exact value: 11195000 USD 2018-01-01 – 2018-12-31: 11195000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2018-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 11195000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11195000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm#3522641 Filing: 000156459021006983 The citation records this snapshot. The page link may show a newer release later.	−USD 122.96 million Calculation and evidence -111767000 − 11195000 USD Exact free cash flow: -122962000 USD 2018-01-01 – 2018-12-31: -111767000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 11195000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2018-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -122962000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -111767000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm#3511793 Filing: 000156459021006983 Input fundies:CapitalExpenditure: 11195000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm#3522641 Filing: 000156459021006983 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 292.07 million Exact value Exact value: -292068000 USD 2019-01-01 – 2019-12-31: -292068000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2019-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -292068000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -292068000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017022003472/srne-20211231.htm#5710373 Filing: 000095017022003472 The citation records this snapshot. The page link may show a newer release later.	−USD 173 million Exact value Exact value: -172996000 USD 2019-01-01 – 2019-12-31: -172996000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2019-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -172996000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -172996000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017022003472/srne-20211231.htm#3653122 Filing: 000095017022003472 The citation records this snapshot. The page link may show a newer release later.	USD 11.44 million Exact value Exact value: 11442000 USD 2019-01-01 – 2019-12-31: 11442000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2019-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 11442000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11442000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017022003472/srne-20211231.htm#3669051 Filing: 000095017022003472 The citation records this snapshot. The page link may show a newer release later.	−USD 184.44 million Calculation and evidence -172996000 − 11442000 USD Exact free cash flow: -184438000 USD 2019-01-01 – 2019-12-31: -172996000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 11442000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2019-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -184438000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -172996000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017022003472/srne-20211231.htm#3653122 Filing: 000095017022003472 Input fundies:CapitalExpenditure: 11442000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017022003472/srne-20211231.htm#3669051 Filing: 000095017022003472 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 298.46 million Exact value Exact value: -298461000 USD 2020-01-01 – 2020-12-31: -298461000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2020-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -298461000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -298461000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#6378591 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 159.54 million Exact value Exact value: -159536000 USD 2020-01-01 – 2020-12-31: -159536000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2020-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -159536000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -159536000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4289953 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	USD 6.53 million Exact value Exact value: 6528000 USD 2020-01-01 – 2020-12-31: 6528000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2020-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 6528000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6528000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4306956 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 166.06 million Calculation and evidence -159536000 − 6528000 USD Exact free cash flow: -166064000 USD 2020-01-01 – 2020-12-31: -159536000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 6528000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2020-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -166064000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -159536000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4289953 Filing: 000095017023008238 Input fundies:CapitalExpenditure: 6528000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4306956 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 428.33 million Exact value Exact value: -428325000 USD 2021-01-01 – 2021-12-31: -428325000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2021-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -428325000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -428325000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#6376335 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 281.82 million Exact value Exact value: -281821000 USD 2021-01-01 – 2021-12-31: -281821000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2021-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -281821000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -281821000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4287758 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	USD 8.87 million Exact value Exact value: 8871000 USD 2021-01-01 – 2021-12-31: 8871000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2021-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 8871000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8871000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4304772 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 290.69 million Calculation and evidence -281821000 − 8871000 USD Exact free cash flow: -290692000 USD 2021-01-01 – 2021-12-31: -281821000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 8871000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2021-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -290692000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -281821000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4287758 Filing: 000095017023008238 Input fundies:CapitalExpenditure: 8871000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4304772 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 572.84 million Exact value Exact value: -572843000 USD 2022-01-01 – 2022-12-31: -572843000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Net Income: -572843000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -572843000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#6374079 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 293.86 million Exact value Exact value: -293857000 USD 2022-01-01 – 2022-12-31: -293857000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Operating Cash Flow: -293857000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -293857000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4285563 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	USD 13.66 million Exact value Exact value: 13657000 USD 2022-01-01 – 2022-12-31: 13657000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Capital Expenditure: 13657000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13657000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4302587 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.	−USD 307.51 million Calculation and evidence -293857000 − 13657000 USD Exact free cash flow: -307514000 USD 2022-01-01 – 2022-12-31: -293857000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 13657000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SORRENTO THERAPEUTICS, INC. · 2022-12-31 SORRENTO THERAPEUTICS, INC. (edgar:850261) Free cash flow: -307514000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:59:39Z Snapshot: b6a0e6799428ea40b7565fe20ef82a17c640966ed4e096a67e8c45bd837b7b49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/850261?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -293857000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4285563 Filing: 000095017023008238 Input fundies:CapitalExpenditure: 13657000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm#4302587 Filing: 000095017023008238 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

126 filings · 4,295 latest values · 4,295 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000850261, 850261, SRNE, SRNEQ, edgar:850261

Also known as QUIKBYTE SOFTWARE INC, SORRENTO THERAPEUTICS, INC., Sorrento Therapeutics, Inc.

SORRENTO THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation